149 related articles for article (PubMed ID: 14570757)
1. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918.
Wu CY; Benet LZ
Drug Metab Dispos; 2003 Nov; 31(11):1292-5. PubMed ID: 14570757
[TBL] [Abstract][Full Text] [Related]
2. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay.
Lau YY; Wu CY; Okochi H; Benet LZ
J Pharmacol Exp Ther; 2004 Mar; 308(3):1040-5. PubMed ID: 14634033
[TBL] [Abstract][Full Text] [Related]
3. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
Cummins CL; Salphati L; Reid MJ; Benet LZ
J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay.
Lam JL; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Aug; 34(8):1336-44. PubMed ID: 16698890
[TBL] [Abstract][Full Text] [Related]
5. Role of P-glycoprotein in the hepatic metabolism of tacrolimus.
Jeong H; Chiou WL
Xenobiotica; 2006 Jan; 36(1):1-13. PubMed ID: 16507509
[TBL] [Abstract][Full Text] [Related]
6. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.
Lam JL; Benet LZ
Drug Metab Dispos; 2004 Nov; 32(11):1311-6. PubMed ID: 15483198
[TBL] [Abstract][Full Text] [Related]
7. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
8. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
Ward KW; Azzarano LM
J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727
[TBL] [Abstract][Full Text] [Related]
10. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems.
Hoffmaster KA; Zamek-Gliszczynski MJ; Pollack GM; Brouwer KL
J Pharmacol Exp Ther; 2004 Dec; 311(3):1203-10. PubMed ID: 15302892
[TBL] [Abstract][Full Text] [Related]
11. Disposition of amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Pharmacol; 2004 Jan; 56(1):35-41. PubMed ID: 14979999
[TBL] [Abstract][Full Text] [Related]
12. Hepatic disposition of cyclosporine A in isolated perfused rat livers.
Mehvar R; Chimalakonda AP
J Pharm Pharm Sci; 2004 Feb; 7(1):47-54. PubMed ID: 15144734
[TBL] [Abstract][Full Text] [Related]
13. MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver.
Liu Y; Huang L; Hoffman T; Gosland M; Vore M
Cancer Res; 1996 Nov; 56(21):4992-7. PubMed ID: 8895755
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits.
Sinko PJ; Kunta JR; Usansky HH; Perry BA
J Pharmacol Exp Ther; 2004 Jul; 310(1):359-66. PubMed ID: 15004217
[TBL] [Abstract][Full Text] [Related]
15. Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide.
Tong Y; Zhang R; Ngo SN; Davey AK
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):685-9. PubMed ID: 16895540
[TBL] [Abstract][Full Text] [Related]
16. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein.
Maezono S; Sugimoto K; Sakamoto K; Ohmori M; Hishikawa S; Mizuta K; Kawarasaki H; Watanabe Y; Fujimura A
Pediatr Transplant; 2005 Jun; 9(3):315-23. PubMed ID: 15910387
[TBL] [Abstract][Full Text] [Related]
17. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine.
Dorababu M; Nishimura A; Prabha T; Naruhashi K; Sugioka N; Takada K; Shibata N
Biomed Pharmacother; 2009 Nov; 63(9):697-702. PubMed ID: 19819100
[TBL] [Abstract][Full Text] [Related]
18. Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
Machavaram KK; Gundu J; Yamsani MR
Pharmazie; 2004 Dec; 59(12):957-60. PubMed ID: 15638086
[TBL] [Abstract][Full Text] [Related]
19. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine.
Saitoh H; Saikachi Y; Kobayashi M; Yamaguchi M; Oda M; Yuhki Y; Achiwa K; Tadano K; Takahashi Y; Aungst BJ
Eur J Pharm Sci; 2006 May; 28(1-2):34-42. PubMed ID: 16457995
[TBL] [Abstract][Full Text] [Related]
20. Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver.
Turkanovic J; Ngo SN; Milne RW
J Pharm Pharmacol; 2009 Aug; 61(8):1037-42. PubMed ID: 19703347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
